January 7, 2014 | Six weeks following its decision to suspend development of its flagship drug for treatment of pancreatic cancer, Israeli biomed company BioCancell is planning to raise up to NIS 9 million (approx. $2.57 million) in a rights issue. The funds will be directed towards the Phase III trial of the company’s treatment for bladder cancer. TheMarker reports that The company estimates that the funds should be sufficient for maintaining operation at least through Q3 2014.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

AI Startup Helps Doctors Analyze Heart Scans
February 08, 2023

AI Monitors High-Speed Conveyor Belts For Defects
February 08, 2023

Israel Hi-Tech Group In Rescue Mission To Turkey
February 08, 2023

Israeli Startup Tests Cancer Treatment With Pharma Giant
February 07, 2023
Facebook comments